Literature DB >> 3382171

Successful chemotherapy for recurrent malignant oligodendroglioma.

J G Cairncross1, D R Macdonald.   

Abstract

Eight consecutive patients with recurrent malignant oligodendroglioma were treated with systemic chemotherapy. Six patients received a combination of procarbazine, lomustine (CCNU), and vincristine; 1 received carmustine (BCNU), and 1 diaziquone. All responded by clinical and computed tomographic scan criteria. One patient had a complete response for 78 weeks, and 7 patients had unequivocal partial responses lasting 30+ to 68+ weeks. Two partial responders had complete control of systemic metastases. Malignant oligodendroglioma is a uniquely chemosensitive glial tumor.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3382171     DOI： 10.1002/ana.410230408

Source DB:  PubMed          Journal:  Ann Neurol        ISSN： 0364-5134            Impact factor:   10.422


  77 in total

1.  Thallium-201 SPECT as response parameter for PCV chemotherapy in recurrent glioma.

Authors:  M F Roesdi; T J Postma; O S Hoekstra; C J van Groeningen; J G Wolbers; J J Heimans
Journal:  J Neurooncol       Date:  1998-12       Impact factor: 4.130

Review 2.  Glioma classification: a molecular reappraisal.

Authors:  D N Louis; E C Holland; J G Cairncross
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

3.  Initial treatment patterns over time for anaplastic oligodendroglial tumors.

Authors:  Katherine S Panageas; Fabio M Iwamoto; Timothy F Cloughesy; Kenneth D Aldape; Andreana L Rivera; April F Eichler; David N Louis; Nina A Paleologos; Barbara J Fisher; Lynn S Ashby; J Gregory Cairncross; Gloria B Roldán Urgoiti; Patrick Y Wen; Keith L Ligon; David Schiff; H Ian Robins; Brandon G Rocque; Marc C Chamberlain; Warren P Mason; Susan A Weaver; Richard M Green; Francois G Kamar; Lauren E Abrey; Lisa M Deangelis; Suresh C Jhanwar; Marc K Rosenblum; Andrew B Lassman
Journal:  Neuro Oncol       Date:  2012-05-31       Impact factor: 12.300

4.  Lhx3 is required to maintain cancer cell development of high-grade oligodendroglioma.

Authors:  Hongliang Liu; Wei Liu; Bin Zhu; Qiang Xu; Xiaowei Ni; Ji Yu
Journal:  Mol Cell Biochem       Date:  2014-11-16       Impact factor: 3.396

5.  Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean Radiation Oncology Group study 13-12.

Authors:  Tosol Yu; Hyun-Cheol Kang; Do Hoon Lim; Il Han Kim; Woong-Ki Chung; Chang-Ok Suh; Byung Ock Choi; Kwan Ho Cho; Jae Ho Cho; Jin Hee Kim; Chul-Kee Park; Yong-Kil Hong; In Ah Kim
Journal:  J Neurooncol       Date:  2014-11-13       Impact factor: 4.130

6.  Oligodendrogliomas: a short history of clinical developments.

Authors:  Martin J van den Bent
Journal:  CNS Oncol       Date:  2015

7.  Extreme drug resistance in primary brain tumors: in vitro analysis of 64 resection specimens.

Authors:  Raymond I Haroun; Richard E Clatterbuck; M Christopher Gibbons; Peter C Burger; Ricardo Parker; John P Fruehauf; Henry Brem
Journal:  J Neurooncol       Date:  2002-06       Impact factor: 4.130

Review 8.  The basis for current treatment recommendations for malignant gliomas.

Authors:  H A Fine
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

9.  Combined surgery, radiation, and PCV chemotherapy for astrocytomas compared to oligodendrogliomas and oligoastrocytomas WHO grade III.

Authors:  Rudolf A Kristof; Georg Neuloh; Volkmar Hans; Martina Deckert; Horst Urbach; Uwe Schlegel; Matthias Simon; Johannes Schramm
Journal:  J Neurooncol       Date:  2002-09       Impact factor: 4.130

10.  BCNU down-regulates anti-apoptotic proteins bcl-xL and Bcl-2 in association with cell death in oligodendroglioma-derived cells.

Authors:  Richard A Lytle; Zhihong Jiang; Xiao Zheng; Keith M Rich
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.